Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. - Université de Bretagne Occidentale Access content directly
Journal Articles Rheumatology Year : 2015

Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.

Divi Cornec
Valérie Devauchelle-Pensec
Sandrine Jousse-Joulin
Xavier Puéchal
Véronique Le Guern
  • Function : Author
Eric Hachulla
Vincent Goeb
Jacques Morel
Jean Jacques Dubost
  • Function : Author
Petra M Meiners
  • Function : Author
Hendrika Bootsma
  • Function : Author
Alain Saraux

Abstract

To determine which outcome measures detected rituximab efficacy in the Tolerance and Efficacy of Rituximab in Sjögren's Disease (TEARS) trial and to create a composite endpoint for future trials in primary SS (pSS). Post hoc analysis of the multicentre randomized placebo-controlled double-blind TEARS trial. The results were validated using data from two other randomized controlled trials in pSS, assessing rituximab (single-centre trial in the Netherlands) and infliximab, respectively. Five outcome measures were improved by rituximab in the TEARS trial: patient-assessed visual analogue scale scores for fatigue, oral dryness and ocular dryness, unstimulated whole salivary flow and ESR. We combined these measures into a composite endpoint, the SS Responder Index (SSRI), and we defined an SSRI-30 response as a ≥30% improvement in at least two of five outcome measures. In TEARS, the proportions of patients with an SSRI-30 response in the rituximab and placebo groups at 6, 16 and 24 weeks were 47% vs 21%, 50% vs 7% and 55% vs 20%, respectively (P < 0.01 for all comparisons). SSRI-30 response rates after 12 and 24 weeks in the single-centre rituximab trial were 68% (13/19) vs 40% (4/10) and 74% (14/19) vs 40% (4/10), respectively. No significant differences in SSRI-30 response rates were found between infliximab and placebo at any of the time points in the infliximab trial. A core set of outcome measures used in combination suggests that rituximab could be effective and infliximab ineffective in pSS. The SSRI might prove useful as the primary outcome measure for future therapeutic trials in pSS.

Dates and versions

hal-01259499 , version 1 (20-01-2016)

Identifiers

Cite

Divi Cornec, Valérie Devauchelle-Pensec, Xavier Mariette, Sandrine Jousse-Joulin, Jean-Marie Berthelot, et al.. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.. Rheumatology, 2015, 54 (9), pp.1699-708. ⟨10.1093/rheumatology/kev114⟩. ⟨hal-01259499⟩
238 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More